Kyle Greenway, MD MSc FRCPC, is an Assistant Professor in Psychiatry at ±«ÓãÖ±²¥, attending psychiatrist at the Jewish General Hospital, and investigator at the Lady Davis Institute. He conducts clinical, naturalistic, and fundamental research on novel psychiatric interventions, particularly psychedelic-assisted psychotherapies for refractory depressive disorders. He leads the Ketamine-Assisted Therapy service at the Jewish General Hospital, one of only a handful of clinics in the world to offer a psychedelic therapy for severe depression in a public payer system. His work explores the impacts of extra-pharmacological factors on psychedelic and conventional psychiatric treatments, including how treatment protocols can be tailored to individuals based on their unique life experiences and cultures. Before joining ±«ÓãÖ±²¥, Dr. Greenway completed postdoctoral studies at the world-leading Imperial College Psychedelic Research Centre, as well as the ±«ÓãÖ±²¥ Clinical Investigator Program.
kyle.greenway [at] mail.mcgill.ca (Email)Ìý´¥
Selected Articles
Greenway, K. T., Garel, N., Dinh-Williams, L. A. L., Beaulieu, S., Turecki, G., Rej, S., & Richard-Devantoy, S. (2024). Music as an Intervention to Improve the Hemodynamic Response of Ketamine in Depression: A Randomized Clinical Trial. JAMA Network Open, 7(2), e2354719-e2354719.
Garel, N., Drury, J., Lévesque, J. T., Goyette, N., Lehmann, A., Looper, K., ... & Greenway, K. T. (2023). The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression. Frontiers in Psychiatry, 14.
Garel, N., Lévesque, J. T., Sandra, D. A., Lessard-Wajcer, J., Solomonova, E., Lifshitz, M., ... & Greenway, K. T. (2023). Imprinting: expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings. Frontiers in Human Neuroscience, 17.